Related Experiment Videos
Glycolytic Reprogramming in Endometriosis: Biological Basis and Emerging Targets for Disease-Modifying Therapy
Catarina Sobral1,2,3, Julieta Afonso1,2, Jorge Correia-Pinto1,2,4
1Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal.
Journal of Clinical Medicine
|August 13, 2026
Summary
Endometriosis shares cancer-like metabolic traits, utilizing aerobic glycolysis for survival. Targeting this glycolytic metabolism offers a potential new therapeutic strategy for this chronic gynecological disease.
Area of Science:
- Gynecology
- Oncology
- Metabolic Research
Background:
- Endometriosis is a chronic gynecological condition impacting 10% of reproductive-age women, causing pain and infertility.
- Its exact cause is unknown, but theories include retrograde menstruation and immune system issues.
- Endometriosis exhibits cancer-like characteristics, including uncontrolled cell growth, new blood vessel formation, inflammation, invasion, and immune evasion.
Purpose of the Study:
- To review the clinical features and treatment challenges of endometriosis.
- To explore the emerging evidence of Warburg-like glycolytic metabolism in endometriosis.
- To discuss the potential for repurposing anti-cancer drugs targeting glycolysis.
Main Methods:
- Literature review of clinical studies and preclinical research on endometriosis.
- Analysis of metabolic alterations in endometriotic tissues.
- Comparison of metabolic reprogramming in endometriosis and cancer.
Main Results:
- Endometriotic lesions display a metabolic shift favoring aerobic glycolysis (Warburg effect) over oxidative phosphorylation.
- This metabolic reprogramming supports cancer-like hallmarks, including survival in low-oxygen environments and resistance to cell death.
- Shared hallmarks suggest potential therapeutic overlap with cancer treatments.
Conclusions:
- Endometriosis exhibits Warburg-like metabolism, a key feature shared with cancer.
- Targeting glycolytic pathways presents a promising avenue for novel endometriosis therapies.
- Further preclinical research is needed to address challenges like disease heterogeneity and drug safety before clinical application.
Related Concept Videos
01:29Somatic to iPS Cell Reprogramming
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...
02:07Oogenesis
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
01:24Methods of Nuclear Reprogramming
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for injury repair.